Treatment of Acute Pain in Cats

Johnson, Jacob A.

doi:10.1002/9781118999196.ch25

Cited by 1 publication

(1 citation statement)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite increasing interest and research to bridge this information gap, most information on pain control in cats focuses on perioperative pain and analgesia. 2–5 Less information exists about conditions resulting in chronic pain; consequently, more cats with these conditions remain undiagnosed and under-treated. 6–8 The gradual onset and subtle behavioural changes seen in chronic pain situations, coupled with cats’ abilities to mask clinical signs, likely contribute to this disparity, making identification and measurement of chronic pain problematic.…”

Section: Introductionmentioning

confidence: 99%

Prescribing practices of veterinarians in the treatment of chronic musculoskeletal pain in cats

Adrian

Rishniw²,

Scherk³

et al. 2018

Journal of Feline Medicine and Surgery

View full text Add to dashboard Cite

Objectives Despite the high prevalence and increasing awareness of chronic musculoskeletal pain in cats, approved treatment options are completely lacking in the USA, and few other options have sufficient safety and efficacy data. Knowledge of current prescribing practices should inform future research of putative therapies. We aimed to determine which drug and non-drug therapies were being used by general practitioners for the treatment of musculoskeletal pain in cats and to understand demographic influences on prescribing practices. Methods We distributed a survey to 36,676 veterinarians who were members of the Veterinary Information Network in January 2017. Within 3 weeks, 1056 practitioners completed the survey. The survey included demographic and background information, questions on prescribing frequency and dosing regimen of 13 drugs and non-drug therapies and questions on preferred medication formulations and dosing frequencies. Descriptive statistics were used, as well as χ testing to evaluate relationships between demographic variables and prescription practices. Results Gabapentin was prescribed most frequently (71% of respondents), followed by joint supplements (67.8%), meloxicam (64.0%), opioids (62.6%) fish oil (62.1%) and polysulfated glycosaminoglycans (61.9%). Years in practice appeared to influence prescribing habits, with practitioners graduated for >20 years prescribing glucocorticoids more frequently than other age groups ( P = 0.0002), whereas recent graduates (<1 year) reported prescribing therapies less frequently across all categories. Conclusions and relevance These results show a contrast between therapies prescribed by practitioners and what is supported by evidenced-based literature. Future research evaluating the safety and efficacy of gabapentin should be prioritised.

show abstract